Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Design Therapeutics (DSGN) EPS (Weighted Average and Diluted) (2021)

Design Therapeutics' EPS (Weighted Average and Diluted) history spans 1 years, with the latest figure at -$0.21 for Q3 2021.

  • For Q3 2021, EPS (Weighted Average and Diluted) changed N/A year-over-year to -$0.21; the TTM value through Sep 2021 reached -$0.52, changed N/A, while the annual FY2025 figure was -$1.22, 38.64% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q3 2021 was -$0.21 at Design Therapeutics, down from -$0.14 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.14 in Q2 2021 and bottomed at -$0.21 in Q3 2021.